Kennislacunes

P: patients with metastatic clear cell renal carcinoma

I: immunotherapy + targeted therapy

C: other combinations of immunotherapy + targeted therapy, sunitinib

O: progression-free survival (PFS), overall survival (OS), Quality of Life, adverse events